Abstract
Dendritic cells (DCs) are one of the most potent antigen-presenting cells (APCs). They migrate as precursors from the bone marrow into various organs, where they usually reside in an inactive state (1). However, during this regional residency, these cells can efficiently endocytose and process antigens (2). Upon activation, they undergo a differentiation process that results in decreased antigen-processing capacity and enhanced expression of major histocompatibility complex (MHC) and costimulatory molecules, after which they migrate to the lymphoid organs to interact with or activate naive T cells (3,4). Because of the critical roles DCs have in the generation of primary immune responses, an important avenue of investigation is their potential for modulating immunologic functions, such as the induction of immune tolerance or tumor immunity. Recently, it has been shown that DCs pulsed with tumor-derived MHC class I-restricted peptides or tumor lysates are able to induce significant cytotoxic T-lymphocyte (CTL)-dependent antitumor immune responses in vitro as well as in vivo (5-7). However, the therapeutic efficiency of these DC vaccine strategies has been quite limited, because they have protected against rechallenge with only small numbers of parental tumor cells or inhibited very earlystage-established tumors. Thus, a strategic goal of current cancer vaccine research has become the induction of stronger tumor-specific CTL responses.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Schuler, G., Koch, F., Heufler, C., Kampgen, E., Topar, G., and Romani, N. (1993) Murine epidermal Langerhans cells as a model to study tissue dendritic cells. Adv.Exp. Med. Biol. 329, 243–254.
Steinman, R. M. and Bancherear, J. (1988) Dendritic cells and the control of immunity. Nature 392, 145–152.
Steinman, R., Witmer-Pack, M., and Inaba, K. (1993) Dendritic cells: antigen presentation, accessory function and clinical relevance. Adv. Exp. Med. Biol. 329, 1–9.
Cella, M., Sallusto, F., and Lanzavecchia, A. (1997) Origin, maturation and antigen presenting function of dendritic cells. Curr. Opin. Immunol. 9, 10–16.
Porgador, A., Snyder, D., and Gilboa, E. (1996) Induction of antitumor immunity using bone marrow-generated dendritic cells. J. Immunol. 156, 2918–2926.
Bellone, M., Lezzi, G., Martin-Fontecha, A., Rivolta, L., Manfredi, A., Protti, M., et al. (1997) Rejection of a nonimmunogeneic melanoma by vaccination with natural melanoma peptides on engineered antigen-presenting cells. J. Immunol. 158, 783–789.
Asheley, D., Faiola, B., Nair, S., Hale, L., Bigner, D., and Gilbao, E. (1997) Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induced antitumor immunity against central nervous system tumors. J. Exp. Med. 186, 1177–1182.
Jonuleit, H., Knop, J., and Enk, A. (1996) Cytokines and their effects on maturation, differentiation and migration of dendritic cells. Arch. Dermatol. Res. 289, 1–8.
Caux, C., Dezutter-Dambuyant, C., Schmitt, D., and Banchereau, J. (1992) GMCSF and TNF-α cooperate in the generation of dendritic Langerhans cells. Nature 360, 258–269.
Jonuleit, H., Kuhn, U., Muller, G., Steinbrink, K., Paragnik, L., Schmitt, E., et al. (1997) Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur. J. Immunol. 27, 3135–3142.
Labeur, M., Roters, B., Pers, B., Mehling, A., Luger, T., Schwarz, T., et al. (1999) Generation of tumor immunity by bone marrow-derived dendritic cells correlates with dendritic cell maturation stage. J. Immunol. 162, 168–175.
Sallusto, F., Cella, M., Danieli, C., and Lanzavecchia, A. (1995) Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products. J. Exp. Med. 182, 389–400.
Rieser, C., Bock, G., Klocker, H., Bartsch, G., and Thumher, M. (1997) Prostaglandin Ea and tumor necrosis factor alpha cooperate to activate human dendritic cells: synergistic activation of interleukin 12 production. J. Exp. Med. 186, 1603–1608.
Cumberbatch, M. and Kimber, I. (1992) Tumor necrosis factor-α induces dendritic cell migration to draining lymph nodes, and possibly provides one stimulation for Langerhans’ cell migration. Immunology 75, 257–263.
Cumberbatch, M. and Kimber, I. (1995) Tumor necrosis factor-α is required for accumulation of dendritic cells in draining lymph nodes and for optimal contact sensitization. Immunology 84, 31–35.
Kay, M. A., Glorioso, J. C., and Naldini, L. (2001) Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics. Nat. Med. 7, 33–40.
Shenk, T. (1996) Adenoviruses: the viruses and their replication, in Fields Virology, 3rd ed (Fields, B. N., Knipe, D. M., and Howley, P. M., eds.), Lippincott-Raven, Philadelphia, pp. 2111–2148.
Graham, F. and Prevec, L. (1991) Manipulation of adenovirus vectors, in Methods in Molecular Biology (Murray, E. J. and Clifton, N. J., eds.), Humana, Totowa, NJ, pp. 109–128.
Okada, T., Ramsey, W. J., Munir, J., Wildner, O., and Blaese, R. M. (1998) Efficient directional cloning of recombinant adenovirus vectors using DNA-protein complex. Nucl. Acids Res. 26, 1947–1950.
Scarppini, C., Arthur, J., Efstathiou, S., McGrath, Y., and Wilkinson, G. (1999) Herpes simplex virus and adenovirus vectors, in DNA Viruses: A Practical Approach (Cann, J., ed.), Oxford University Press, New York, pp. 267–306.
McGrory, W. J., Bautista, D. S., and Graham, F. L. (1988) A simple technique for the rescue of early region I mutations into infectious human adenovirus type 5. Virology 163, 614–617.
Chartier, C., Degryse, E., Gantzer, M., Dieterle, A., Pavirani, A., and Mehtali, M. (1996) Efficient generation of recombinant adenovirus vectors by homologous recombination in Escherichia coli. J. Virol. 70, 4805–4810.
Fu, S. and Deisseroth, A.B. (1997) Use of the cosmid adenoviral vector cloning system for the in vitro construction of recombinant adenoviral vectors. Hum. Gene Ther. 8, 1321–1330.
Ketner, G., Spencer, F., Tugendreich, S., Connelly, C., and Hieter, P. (1994) Efficient manipulation of the human adenovirus genome as an infectious yeast artificial chromosome clone. Proc. Natl. Acad. Sci. USA 91, 6186–6190.
Boviatsis, E., Chase, M., Wei, M., et al. (1994) Gene transfer into experimental brain tumors mediated by adenovirus, herpes simplex virus and retrovirus. Hum. Gene Ther. 5, 183–191.
Cao, X., Zhang, W., He, L., Xie, Z., Ma, S., Tao, Q., et al. (1998) Lymphotactin gene-modified bone marrow dendritic cells act as more potent adjuvants for peptide delivery to induce specific antitumor immunity. J. Immunol. 161, 6238–6244.
Curiel-Lewandrowski, C., Mahnke, K., Labeur, M., Roters, B., Schmidt, W., Granstein, R., et al. (1999) Transfection of immature murine bone marrow-derived dendritic cells with the granulocyte-macrophage colony-stimulating factor gene potently enhance their in vivo antigen-presenting capacity. J. Immunol. 163, 174–183.
Wright, P., Braun, R., Babiuk, L., Hurk, S., Moyana, T., Zheng, C., et al. (1999) Adenovirus-mediated TNF gene transfer induces significant tumor regression in mice. Cancer Biother. Radiopharm. 14, 49–57.
Hirt, B. (1967) Selective extraction of polyoma DNA from infected mouse cell cultures. J. Mol. Biol. 26, 365–369.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2003 Humana Press Inc.
About this protocol
Cite this protocol
Xiang, J., Wu, J. (2003). Genetic Engineering of Dendritic Cells by Adenovirus-Mediated TNF-α Gene Transfer. In: Körholz, D., Kiess, W. (eds) Cytokines and Colony Stimulating Factors. Methods in Molecular Biology, vol 215. Humana, Totowa, NJ. https://doi.org/10.1385/1-59259-345-3:213
Download citation
DOI: https://doi.org/10.1385/1-59259-345-3:213
Publisher Name: Humana, Totowa, NJ
Print ISBN: 978-1-58829-035-9
Online ISBN: 978-1-59259-345-3
eBook Packages: Springer Protocols